Antigenic Hsp70–peptide upregulate altered cell surface MHC class I expression in TAMs and increases anti-tumor function in Dalton’s lymphoma bearing mice

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 2023-2032

  Gautam, Pramod Kumar ^a   Acharya, Arbind ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Hsp70 peptide complex; Macrophage; MHC class I (H2Db); Tumor progression; Tumor associated macrophages

Indexed keywords

HEAT SHOCK PROTEIN 70; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; CELL COMMUNICATION; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGY; INFLAMMATION; LYMPHOMA; MACROPHAGE; MALE; MOUSE; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL COMMUNICATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HSP70 HEAT-SHOCK PROTEINS; INFLAMMATION; LYMPHOMA; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 84930891517     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2809-9     Document Type: Article

References (45)

1. Forngaleg-Behia EB, Doseff AI. Regulation of monocytes and macrophages cell fate. Front Biosci. 2008;14:2413–31.
2. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–12.
3. Subauste CS, Malefyt RDW, Fuh F. Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen. J Immunol. 1998;160:1831–40.
4. Nardin A, Anastado JP. Macrophage and cancer. Front Biosci. 2008;13:3494–505.
5. Ramachandra L, Chu RS, Askew D, Noss EH, et al. Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. Immunol Rev. 1999;168:217–39.
6. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumour growth. Immunol Today. 2000;21:455–64.
7. Costello RGT, Mallet FO, Sainty D, et al. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol. 1998;28:90–03.
8. Levin I, Klein T, Kuperman O, Segal S, Shapira J, Gal R, et al. The expression of HLA class I antigen in prostate cancer in relation to tumour differentiation and patient survival. Cancer Detect Prev. 1994;18:443–45.
9. Maddalena M, Emilia A, Lisa V. HLA-dependent tumour development: a role for tumour associate macrophages? J Transl Med. 2013;11(247):1–15.
10. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–89.
11. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.
12. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.
13. Mahoney KH, Heppner GH. Facs analysis of tumor- associated macrophages replication: differentiation between metastasis and nonmetastasic murine mammary tumor. J Leukoc Biol. 1987;41:205–11.
14. Solinas G, Germano G, Mantovani A, Allavena AP, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.
15. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–17.
16. Siveen KS, Kuttan G. Role of macrophage in tumor progression. Immunol Lett. 2009;123:97–02.
17. Villadangos JA, Schnorrer P, Wilson NS. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev. 2005;207:191–05.
18. Botond ZI, Daniel HK. Antigen presentation by Langerhans cells. Curr Opin Immunol. 2013;25:115–19.
19. Jattela M. Heat shock proteins as cellular lifeguards. Ann Med. 1999;31:261–71.
20. Blachere NE, Li Z, Chandawarkar RY, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytoxic T-lymphocytes response and tumor immunity. J Exp Med. 1997;186:1315–27.
21. Tamura Y, Peng P, Liu K, et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117–20.
22. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178:1391–96.
23. Tokuda Y, Tsuji M, Yamazaki M, et al. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob Agents Chemother. 1993;37:2228–30.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–85.
25. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria S, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytoxic T-lymphocytes response and tumor immunity. J Exp Med. 1997;186:1315–27.
26. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997;278:117–20.
27. Laugel B, Cole DK, Clement M, Wooldridge L, Price DA, Sewell AK. The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells. J Leukoc Biol. 2011;90:1089–99.
28. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8:607–18.
29. Groothuis TA, Griekspoor AC, Neijssen JJ, Herberts CA, Neefjes JJ. MHC class I alleles and their exploration of the antigen-processing machinery. Immunol Rev. 2005;207:60–76.
30. Nitta T, Murata S, Sasaki K, Fujii H, Ripen AM, Ishimaru N, et al. Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells. Immunity. 2010;32:29–40.
31. Odile B, Jean Fran OB, Heltne Z, Alain I, Philippe K, Jean D. Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression. Proc Natl Acad Sci U S A. 1992;89:3488–92.
32. Blades RA, Er CS, Patrick J, Keating MRCOG. Loss of Hla class i expression in prostate cancer: implications for immunotherapy. Urology. 1995;46(5):681–87.
33. Villadangos JA, Schnorrer P, Wilson NS. Control of MHC class II antigen presentation in dendritic cells: a balance between creative and destructive forces. Immunol Rev. 2005;207:191–05.
34. Juergen B, Simon J, Barbara S. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol. 2012;22:350–58.
35. Shi C, Zhu Y, Su Y, Chung LWK, Cheng T. β2-Microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today. 2009;14(1/2):25–30.
36. Rowley DR et al. b-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor b1 action. Cancer Res. 1995;55:781–6.
37. Huang WC et al. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006;66:9108–16.
38. Nomura T et al. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMPresponsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res. 2006;12:7294–05.
39. Mori M et al. Antitumor effect of b2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kB. Cancer Res. 2001;61:4414–17.
40. Min R et al. b2-Microglobulin as a negative growth regulator of myeloma cells. Br J Haematol. 2002;118:495–05.
41. Gordon J et al. Beta2-microglobulin induces caspase-dependent apoptosis in the CCRF-HSB-2 human leukemia cell line independently of the caspase-3, -8 and -9 pathways but through increased reactive oxygen species. Int J Cancer. 2003;103:316–27.
42. Shahoo NC, Rao KVS, Natrajan K. CD80 expression is induced on activated B cell following stimulation by CD86. Scand J Immunol. 2002;55:577–84.
43. Campillo JA, Martínez-Escribano JA, Muro M, Moya-Quiles R. HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis. Immunogenetics. 2006;57(12):926–33.
44. Christianson GJ et al. β2-Microglobulin-deficient mice are protected from hyper-gammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol. 1997;159:4781–92.
45. Hoglund P et al. b2-Microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. Eur J Immunol. 1998;28:370–8.